Share information
249.60 €
-1.19 %
13/03/2026 17:35
-1.19 %
Open
High
Low
Volume
252.40 €
256.10 €
248.70 €
212,641
Latest News
11-Mar-2026
BIMZELX[®]▼(bimekizumab) superior to SKYRIZI[®] (risankizumab) in BE BOLD: first head-to-head study in active psoriatic arthritis (PsA) to demonstrate superiority in ACR50
03-Mar-2026
UCB and Antengene enter global license agreement for ATG-201, a B cell-depleting bispecific antibody
26-Feb-2026
Strong Execution Fueling Sustained Company Growth
04-Feb-2026
UCB showcases three-year hidradenitis suppurativa data at EHSF: BIMZELX[®]▼(bimekizumab) achieved inflammatory lesion resolution and substantial disease severity improvements